Cite

HARVARD Citation

    Toh, U. et al. (2020). Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer. Cancer science. 111 (8), pp. 2760-2769. [Online]. 
  
Back to record